NZ600978A - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
NZ600978A
NZ600978A NZ600978A NZ60097810A NZ600978A NZ 600978 A NZ600978 A NZ 600978A NZ 600978 A NZ600978 A NZ 600978A NZ 60097810 A NZ60097810 A NZ 60097810A NZ 600978 A NZ600978 A NZ 600978A
Authority
NZ
New Zealand
Prior art keywords
klh
linker
egfrviii conjugate
peptide
interact
Prior art date
Application number
NZ600978A
Other languages
English (en)
Inventor
Ferhana Zaman
Lavinia Marina Lewis
Brandi Rae Osborne
Sandipan Sinha
Jennifer Marie Thorn
Syed Saleem Ahmed
Iii John Joseph Buckley
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Priority to NZ629256A priority Critical patent/NZ629256A/en
Publication of NZ600978A publication Critical patent/NZ600978A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ600978A 2009-12-22 2010-12-08 Vaccine compositions NZ600978A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ629256A NZ629256A (en) 2009-12-22 2010-12-08 Vaccine compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Publications (1)

Publication Number Publication Date
NZ600978A true NZ600978A (en) 2014-08-29

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ629256A NZ629256A (en) 2009-12-22 2010-12-08 Vaccine compositions
NZ600978A NZ600978A (en) 2009-12-22 2010-12-08 Vaccine compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ629256A NZ629256A (en) 2009-12-22 2010-12-08 Vaccine compositions

Country Status (13)

Country Link
US (3) US20130034573A1 (cg-RX-API-DMAC7.html)
EP (2) EP2515934B1 (cg-RX-API-DMAC7.html)
JP (2) JP6007105B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120120185A (cg-RX-API-DMAC7.html)
CN (2) CN102762224A (cg-RX-API-DMAC7.html)
AU (1) AU2010334428B2 (cg-RX-API-DMAC7.html)
CA (1) CA2785585A1 (cg-RX-API-DMAC7.html)
IL (1) IL220308A0 (cg-RX-API-DMAC7.html)
MX (1) MX337070B (cg-RX-API-DMAC7.html)
NZ (2) NZ629256A (cg-RX-API-DMAC7.html)
RU (1) RU2581020C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201408505SA (cg-RX-API-DMAC7.html)
WO (1) WO2011077309A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2536399T3 (pl) * 2010-02-21 2020-06-29 Bayer Healthcare Llc Sposób aktywacji i sprzęgania biocząsteczek
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3106297C (en) * 2018-07-19 2024-10-08 Helixmith Co., Ltd. LYOPHILIZED PHARMACEUTICAL COMPOSITIONS INTENDED FOR NAKED DNA GENE THERAPY
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (cg-RX-API-DMAC7.html) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ATE262586T1 (de) 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CA2268825C (en) 1996-10-11 2006-04-18 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
DE69821246T2 (de) * 1997-07-31 2004-11-04 Metra Biosystems, Inc., Mountain View Testverfahren für collagenpeptid
EP1007546B1 (en) * 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molecular mimetics of meningococcal b epitopes
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
AU783344B2 (en) 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
TWI281403B (en) 1999-03-19 2007-05-21 Smithkline Beecham Biolog Vaccine
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EP3192528A1 (en) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
AU2003257850A1 (en) * 2002-08-14 2004-03-03 Mitsubishi Kagaku Iatron, Inc. ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
JP4808614B2 (ja) * 2003-06-27 2011-11-02 アムジエン・フレモント・インコーポレイテツド 上皮成長因子受容体の欠失型変異体を認識する抗体、およびそれらの使用
DK1684719T3 (da) * 2003-11-14 2012-01-30 Baxter Int Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
ATE500848T1 (de) * 2005-05-24 2011-03-15 Neovacs Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein
RU2473560C2 (ru) * 2005-11-02 2013-01-27 Дьюк Юниверсити Совместная химиотерапия и иммунотерапия
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
SG10201608059VA (en) * 2007-12-28 2016-11-29 Baxter Int Recombinant vwf formulations

Also Published As

Publication number Publication date
SG181628A1 (en) 2012-07-30
US20150087815A1 (en) 2015-03-26
AU2010334428B2 (en) 2015-05-21
WO2011077309A3 (en) 2011-10-06
CN102762224A (zh) 2012-10-31
JP2015180667A (ja) 2015-10-15
EP2515934A2 (en) 2012-10-31
US20190365886A1 (en) 2019-12-05
JP6007105B2 (ja) 2016-10-12
MX337070B (es) 2016-02-11
EP2515934B1 (en) 2017-05-17
EP3257525A2 (en) 2017-12-20
CA2785585A1 (en) 2011-06-30
RU2581020C2 (ru) 2016-04-10
IL220308A0 (en) 2012-07-31
MX2012007283A (es) 2012-07-30
RU2012131162A (ru) 2014-01-27
AU2010334428A1 (en) 2012-07-05
JP2013515049A (ja) 2013-05-02
EP3257525A3 (en) 2018-02-28
US20130034573A1 (en) 2013-02-07
CN107412754A (zh) 2017-12-01
NZ629256A (en) 2016-02-26
JP6146927B2 (ja) 2017-06-14
WO2011077309A2 (en) 2011-06-30
KR20120120185A (ko) 2012-11-01
SG10201408505SA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
EP3708581A3 (en) A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
NZ626302A (en) Bispecific binding molecules for anti-angiogenesis therapy
WO2011036564A3 (en) Hyperblebbing shigella strains
HK1202067A1 (en) Therapeutic agents comprising insulin amino acid sequences
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2014097099A3 (en) Glycoconjugation process
UA105785C2 (uk) Спосіб очищення ліпопептидів
WO2012099973A3 (en) Compositions and methods for treating cancer
NZ628756A (en) Immunogens for hiv vaccination
NZ612161A (en) Radiolabled her2 binding peptides
PH12012501831B1 (en) Protein ipa1 related to plant architecture, its coding genes and uses
MX338828B (es) Lote maestro y proceso para la preparacion de una composicion polimerica.
HK1198170A1 (en) Pseudomonas exotoxin a with less immunogenic b cell epitopes
WO2010093182A3 (ko) Ｌ-아미노산 생산용 미생물 및 이를 이용하여 ｌ-아미노산을 생산하는 방법
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
NZ600978A (en) Vaccine compositions
GB201017519D0 (en) Vaccines
EA201170477A1 (ru) СПОСОБ СИНТЕЗА (Aib)hGLP-1(7-36)-NH
WO2009072555A1 (ja) 癌ワクチン
MX2009000756A (es) Uso de multiples secuencias potenciadoras de la transformacion para mejorar la eficiencia de la transformacion en planta.
WO2009098147A3 (en) Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanion for the treatment of aids
MX2010010177A (es) Fragmentos de beta timosina mejorada.
MX2013010688A (es) Moleculas conjugadas nuevas que comprendenun peptido derivado del receptor cd4 acoplado a un polipeptido polianionico para el tratamiento de sida.
MY156568A (en) Peptide-polymer conjugates
WO2011031764A3 (en) Compounds and related methods of use

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2015 BY COMPUTER PACKAGES INC

Effective date: 20150303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20151118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161118

LAPS Patent lapsed